Taking care of your prostate is critical for living with prostate cancer. A regular PSA test can help detect this silent disease in the early stages. Without regular screening, the vast majority of older men would die of prostate cancer before it was diagnosed. If detected early, prostate cancer is treatable and can be cured in ten to twenty years. Many men do not know that chronic inflammation is linked to a range of other diseases, including cardiovascular disease, type 2 diabetes, and type 3 cancer. The Harvard Medical School recommends several ways to fight inflammation, including using natural products.
The largest 8% of men with low-risk prostate cancer progress to higher-grade disease. Fortunately, most patients who develop Low-Risk disease will not progress to high-grade disease. The remaining men can defer treatment for life, while focal therapies are available for men with localized high-risk disease. But the fact that 30% of men with low-risk disease develop the disease in later stages may require early treatment. However, in the event that the disease does progress, a prostate biopsy may be necessary.
The clinical trial is being conducted by Dr. Song-Chu Ko, a professor of radiation oncology at Indiana University’s Melvin and Bren Simon Cancer Center. The trial will evaluate the targeting molecule’s effectiveness at detecting prostate cancer and delivering the radioimaging agent. The trial is currently underway in two clinical trials. The results of this trial will determine whether the new treatment can prevent prostate cancer from recurring or not.
The PSMA imaging agent is particularly sensitive for the detection of prostate cancer. PSMA is a molecule that is expressed exclusively by prostate cancer cells. Any other cells that contain prostate cancer cells cannot take up the PSMA imaging agent. It will be absorbed by only malignant cells, so the test has a high sensitivity. If it can detect prostate cancer, it is a promising treatment option. If you have any questions about PSMA imaging, please contact us.
The Gleason score was first developed in the 1960s. It ranked malignant tissue based on glandular patterns in prostate biopsy samples. Malignancies with Gleason patterns 4+3=7 had a significantly worse prognosis than cancers with Gleason scores of two or three. Today, however, the Gleason scores are accurate and help physicians identify prostate cancer more accurately. A doctor may recommend a different treatment for a patient based on their Gleason score.
